A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
← catalyst calendarNCT05663515 · readout in 43 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With IQVIA Pvt. Ltd.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
24,000estimated
Sites
8
Countries
Denmark, Finland, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-30 | actual | When the study began enrolling |
| Primary completion | 2026-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pancreatic Cancer
Interventions
- Drug: Exenatide — also filed as BYETTA, BYDUREON/BYDUREON BCise
- Drug: Non-GLP-1 RA based glucose lowering drugs — also filed as Insulin/analogues (excl. A10AE54, A10A56), Biguanide, Sulfonylurea, Sulfonamide (heterocycl.), combined oral GLD (excl. DPP-4i), Alpha glucose inhib., Thiazolidinedione, SGLT2i, Oth. GLD excl. insulin
Primary outcomes
what the primary-completion date above is the date OFIncidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population
measured Follow-up starts from the index date to the study completion, an average of 1.5 years or less
Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population
measured Follow-up starts from thr index date to the study completion, an average of 1.5 years or less
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed